Dusseldorf - Delayed Quote EUR

Amicus Therapeutics Inc (AM6.DU)

9.30

+0.25

+(2.76%)

As of 4:31:19 PM GMT+1. Market Open.

Is Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology […]

Insider Monkey 9 days ago

FOLD
Amicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside Potential

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech Stocks While 2024 was a “challenging” year for biotech stocks, […]

Insider Monkey 13 days ago

FOLD
Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook

FOLD reports preliminary fourth-quarter and full-year 2024 total revenues. The company also outlines key strategic goals for 2025.

Zacks 17 days ago

FOLD

TEVA
Shareholders in Amicus Therapeutics (NASDAQ:FOLD) have lost 32%, as stock drops 3.0% this past week

The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...

Simply Wall St. 17 days ago

FOLD
Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® + Opfolda® Total Revenue Growth of 17-24% at CER Expected in 2025 >3,000 People Treated with an Amicus Therapy Today2 PRINCETON, N.J., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today provided its preliminary

GlobeNewswire 17 days ago

FOLD
Is Amicus Therapeutics (FOLD) the Best Medical Stock to Buy Under $20?

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at where Amicus Therapeutics, Inc. (NASDAQ:FOLD) stands against the other best medical stocks under $20. The medical industry plays a crucial role in ensuring the health and safety of populations. Driven […]

Insider Monkey 18 days ago

FOLD
Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 3:00 p.m. PT. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Ther

GlobeNewswire 28 days ago

FOLD
HALO or FOLD: Which Is the Better Value Stock Right Now?

HALO vs. FOLD: Which Stock Is the Better Value Option?

Zacks last month

HALO

FOLD
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh

Benzinga last month

IMRX

FOLD

IMCR
Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks last month

FOLD
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

FOLD

APLS
HALO vs. FOLD: Which Stock Is the Better Value Option?

HALO vs. FOLD: Which Stock Is the Better Value Option?

Zacks last month

HALO

FOLD
Exploring High Growth Tech Stocks In The United States December 2024

The United States market has been flat over the last week but is up 32% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.

Simply Wall St. last month

CDNA

DVAX

FOLD
HALO vs. FOLD: Which Stock Should Value Investors Buy Now?

HALO vs. FOLD: Which Stock Is the Better Value Option?

Zacks 2 months ago

FOLD

HALO
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Amicus Therapeutics ( NASDAQ:FOLD ) Third Quarter 2024 Results Key Financial Results Revenue: US$141.5m (up 37% from 3Q...

Simply Wall St. 2 months ago

FOLD
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated

FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024.

Zacks 2 months ago

FOLD

TEVA
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 2 months ago

FOLD
Amicus Therapeutics Inc (FOLD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Amicus Therapeutics Inc (FOLD) reports a 37% revenue increase and raises full-year guidance, despite ongoing litigation challenges.

GuruFocus.com 2 months ago

FOLD
Q3 2024 Amicus Therapeutics Inc Earnings Call

Q3 2024 Amicus Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

FOLD
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings

The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 2 months ago

FOLD

Performance Overview

Return	AM6.DU	S&P 500
YTD	+3.33%	+2.43%
1-Year	-19.83%	+22.78%
3-Year	+16.98%	+36.52%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amicus Therapeutics Inc (AM6.DU)

Is Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Amicus Therapeutics, Inc. (FOLD): The Biotech Stock with Biggest Upside Potential

Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook

Shareholders in Amicus Therapeutics (NASDAQ:FOLD) have lost 32%, as stock drops 3.0% this past week

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

Is Amicus Therapeutics (FOLD) the Best Medical Stock to Buy Under $20?

Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

HALO or FOLD: Which Is the Better Value Stock Right Now?

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?

Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?

HALO vs. FOLD: Which Stock Is the Better Value Option?

Exploring High Growth Tech Stocks In The United States December 2024

HALO vs. FOLD: Which Stock Should Value Investors Buy Now?

Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated

Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock

Amicus Therapeutics Inc (FOLD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Q3 2024 Amicus Therapeutics Inc Earnings Call

Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings

Performance Overview